There were a higher proportion of patients with comorbidities, history of malignant tumor, CVC, mitomycin, recombinant human endostatin, EGFR-TKI, Platinum-based chemotherapy, and Bevacizumab in patients who had VTE compared to patients without VTE. This evidence concerns the gene COL18A1 and cancer.